USE OF CK 2 INHIBITOR FOR TREATMENT AND CHEMICAL SENSITIZATION OF TUMOR UNRESPONSIVE TO ANTICANCER AGENT

PROBLEM TO BE SOLVED: To evade chemotherapy resistance of a tumor to a cell proliferation inhibitor.SOLUTION: This invention relates to a method for combined use for administering simultaneously, individually or sequentially a combination of agents containing a casein kinase 2 phosphorylated inhibit...

Full description

Saved in:
Bibliographic Details
Main Authors CASTELLANOS SERRA LILA ROSA, GOMEZ DANIEL EDUARDO, PEREA RODRIGUEZ SILVIO ERNESTO, GIL VALDES JEOVANIS, GONZALEZ LOPEZ LUIS JAVIER, ALONSO DANIEL FERNANDO, ACEVEDO CASTRO BORIS ERNESTO, SANCHEZ PUENTE ANIEL, RAMOS GOMEZ YASSEL, RODRIGUEZ ULLOA ARIELIS, BETANCOURT NUNEZ LAZARO HIRAM, PERERA NEGRIN YASSER, BESADA PEREZ VLADIMIR, FERNANDEZ DE COSSIO DORTA DUQUE JORGE
Format Patent
LanguageEnglish
Published 14.11.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:PROBLEM TO BE SOLVED: To evade chemotherapy resistance of a tumor to a cell proliferation inhibitor.SOLUTION: This invention relates to a method for combined use for administering simultaneously, individually or sequentially a combination of agents containing a casein kinase 2 phosphorylated inhibitor (called as p 15) and a cell proliferation inhibitor used in cancer chemotherapy. A preferable cell proliferation inhibitor is platinum, taxane, Vinca major L. genus alkaloid, 5-fluorouracil, Doxorubicin, Cyclophosphamide, Etoposide, mitomycin C, imatinib, Iressa and velcade (bortezomib). A synergistic effect between the peptide p 15 and an anticancer compound means that the effective concentration of each cell proliferation inhibitor in the method for combined use is lower by 1-2 figures than an effective concentration corresponding to a cell proliferation inhibitor as a single agent. Resultantly, the combination described in this invention has far lower toxicity than toxicity reported relative to an anticancer cell proliferation inhibitor, and the fact is an important advantage for the use thereof in cancer treatment. Further, sequential administration brings about chemical sensitization by premedication of the peptide p 15 of a tumor unresponsive to the anticancer cell proliferation inhibitor.
Bibliography:Application Number: JP20130146681